Literature DB >> 26878133

A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas.

Peter Y Yu1, Mumtaz Y Balkhi2,3,4, Katherine J Ladner2,3, Hansjuerg Alder2,3, Lianbo Yu5, Xiaokui Mo5, William G Kraybill2,6, Denis C Guttridge2,3, O Hans Iwenofu2,7.   

Abstract

Sarcomas are malignant heterogenous tumors of mesenchymal derivation. Emerging data suggest that miRNA might have a causal role in sarcomagenesis. Herein, we used a selective miRNA screening platform to study the comparative global miRNA expression signatures in a cohort of human sarcomas with the caveat that comparisons between tumor and non-tumor cells were performed from the same patients using formalin-fixed paraffin-embedded tissue. Five histologic types were examined that included: myxoid liposarcoma, well-differentiated liposarcoma, dedifferentiated liposarcoma, pleomorphic rhabdomyosarcoma, and synovial sarcoma. In addition, soft-tissue lipomas and normal fat were included as a separate set of controls for the lipogenic tumors. Clustering analysis showed a distinct global difference in expression patterns between the normal and sarcoma tissues. Expression signatures in an unsupervised hierarchical clustering analysis revealed tight clustering in synovial and myxoid liposarcomas, and the least clustering was observed in the pleomorphic rhabdomyosarcoma subtype. MiR-145 showed underexpression in pleomorphic rhabdomyosarcoma, well-differentiated liposarcoma, and synovial sarcoma. Unexpectedly, we found that a set of muscle-specific microRNAs (miRNAs; myomiRs): miR-133, miR-1, and miR-206 was significantly underexpressed in well-differentiated liposarcoma and synovial sarcoma, suggesting that they may function as tumor suppressors as described in muscle-relevant rhabdomyosarcomas. In addition, a tight linear progression of miRNA expression was identified from normal fat to dedifferentiated liposarcoma. These results suggest that miRNA expression profiles could elucidate classes of miRNAs that may elicit tumor-relevant activities in specific sarcoma subtypes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26878133     DOI: 10.1038/labinvest.2015.168

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  46 in total

Review 1.  How microRNAs control cell division, differentiation and death.

Authors:  Eric A Miska
Journal:  Curr Opin Genet Dev       Date:  2005-10       Impact factor: 5.578

2.  MicroRNAs in cancer: personalizing diagnosis and therapy.

Authors:  S Patrick Nana-Sinkam; Muller Fabbri; Carlo M Croce
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

3.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

4.  MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer.

Authors:  Seong O Suh; Yi Chen; Mohd Saif Zaman; Hiroshi Hirata; Soichiro Yamamura; Varahram Shahryari; Jan Liu; Z Laura Tabatabai; Sanjay Kakar; Guoren Deng; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Carcinogenesis       Date:  2011-02-23       Impact factor: 4.944

Review 5.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

6.  Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma.

Authors:  Mitsuru Miyachi; Kunihiko Tsuchiya; Hideki Yoshida; Shigeki Yagyu; Ken Kikuchi; Akiko Misawa; Tomoko Iehara; Hajime Hosoi
Journal:  Biochem Biophys Res Commun       Date:  2010-08-07       Impact factor: 3.575

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.

Authors:  Riccardo Taulli; Francesca Bersani; Valentina Foglizzo; Alessandra Linari; Elisa Vigna; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

9.  NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma.

Authors:  Huating Wang; Ramiro Garzon; Hao Sun; Katherine J Ladner; Ravi Singh; Jason Dahlman; Alfred Cheng; Brett M Hall; Stephen J Qualman; Dawn S Chandler; Carlo M Croce; Denis C Guttridge
Journal:  Cancer Cell       Date:  2008-11-04       Impact factor: 31.743

10.  Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers.

Authors:  Renata A Rawlings-Goss; Michael C Campbell; Sarah A Tishkoff
Journal:  BMC Med Genomics       Date:  2014-08-28       Impact factor: 3.063

View more
  4 in total

1.  Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis.

Authors:  Nikolaos Kapodistrias; Konstantinos Mavridis; Anna Batistatou; Penelope Gogou; Vasilios Karavasilis; Ioannis Sainis; Evangelos Briasoulis; Andreas Scorilas
Journal:  Oncotarget       Date:  2017-01-24

2.  miR-133a function in the pathogenesis of dedifferentiated liposarcoma.

Authors:  Peter Y Yu; Gonzalo Lopez; Danielle Braggio; David Koller; Kate Lynn J Bill; Bethany C Prudner; Abbie Zewdu; James L Chen; O Hans Iwenofu; Dina Lev; Anne M Strohecker; Joelle M Fenger; Raphael E Pollock; Denis C Guttridge
Journal:  Cancer Cell Int       Date:  2018-06-26       Impact factor: 5.722

Review 3.  miRNAs as Biomarkers and Possible Therapeutic Strategies in Synovial Sarcoma.

Authors:  Shaowei Jiang; Ying Hu; Yi Zhou; Guozheng Tang; Wenxu Cui; Xinyi Wang; Bangjie Chen; Zuhong Hu; Bing Xu
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

4.  Circulating MicroRNA-92b-3p as a Novel Biomarker for Monitoring of Synovial Sarcoma.

Authors:  Koji Uotani; Tomohiro Fujiwara; Aki Yoshida; Shintaro Iwata; Takuya Morita; Masahiro Kiyono; Suguru Yokoo; Toshiyuki Kunisada; Ken Takeda; Joe Hasei; Kunihiko Numoto; Yutaka Nezu; Tsukasa Yonemoto; Takeshi Ishii; Akira Kawai; Takahiro Ochiya; Toshifumi Ozaki
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.